🧾 What This Document Is

This is a transcript of a corrected investor conference call from April 6, 2026. Neurocrine Biosciences (NBIX) is explaining its plan to acquire Soleno Therapeutics (SLNO). This call followed the official announcement and is part of the SEC filing process for a tender offer. Think of it as the company's "here's why we're doing this" speech to Wall Street.

👉 In simple terms: Neurocrine is buying Soleno to get its star drug, and this call was their chance to convince investors it's a smart move.

🏢 What The Company Does

Neurocrine Biosciences is a biopharmaceutical company focused on neurological and endocrine disorders. They already have two main drugs:

• INGREZZA: For tardive dyskinesia (a movement disorder).
• CRENESSITY: For congenital adrenal hyperplasia (a rare hormonal disease).

👉 The acquisition target: Soleno Therapeutics is a smaller company whose entire value is built around one key product: VYKAT XR.

💊 The Prize: VYKAT XR

This is the drug Neurocrine is buying. Here’s why it’s a big deal:

• What it treats: Hyperphagia (chronic, life-threatening hunger) in Prader-Willi syndrome (PWS). PWS is a rare genetic disorder affecting about 10,000 people in the US.
• Why it's special: VYKAT XR is the first and only FDA-approved treatment for this core symptom of PWS. It was approved in March 2025 and launched immediately.
• Early success: In its first year (2025), Soleno recorded $190 million in revenue from VYKAT XR, including $92 million in the fourth quarter alone. This shows strong early demand.

👉 Why it matters: Neurocrine believes VYKAT XR has "blockbuster potential" (meaning it could eventually bring in over $1 billion in annual sales) due to the high unmet need in this patient population.

💰 The Deal: Financial Terms

Neurocrine is buying Soleno through a cash tender offer. Here are the key numbers:

• Price per share: $53.00
• Total enterprise value: Approximately $2.9 billion.
• How it's funded: With cash on hand and a "modest level of pre-payable debt." No new shares are being issued.
• Timing: The deal is expected to close in 2026 and be immediately accretive (meaning it will add to Neurocrine's revenue growth from day one).

🚀 Strategic Rationale: Why Do This?

Management gave three main reasons:

1. Accelerate Growth: VYKAT XR instantly boosts Neurocrine's top-line revenue and diversifies its portfolio.
2. Perfect Fit: The drug aligns with Neurocrine's expertise in neuroscience/endocrinology and its strategy of launching first-in-class medicines.
3. Long-Term Value: The acquisition strengthens Neurocrine's position in rare diseases and endocrinology, giving it a third blockbuster-potential product alongside INGREZZA and CRENESSITY.

🔍 Key Questions From Analysts (The Q&A)

The call included a detailed Q&A that revealed more about Neurocrine's thinking:

• On Competition: Executives expressed confidence, noting recent setbacks for competing treatments in development. They believe VYKAT XR is well-positioned as the best-in-class option.
• On Commercial Strategy: The focus will be on continuing the strong launch momentum in the US. They emphasized educating doctors in community settings (not just specialist centers) about the severe behavioral impacts of hyperphagia.
• On Patent Protection: During due diligence, Neurocrine found a "robust patent estate" giving them confidence in exclusivity into the mid-2040s.
• On Europe: For now, no plans to launch in Europe. The entire deal value is based on the US opportunity, mirroring the strategy used for CRENESSITY. They want to focus all resources on a successful US rollout.
• On Safety: Management is confident, citing over 50 years of historical data on the active ingredient (diazoxide) and long-term clinical data showing a manageable risk-benefit profile for PWS.

⚖️ Strengths & Risks

👍 Strengths:

• Adds a proven, revenue-generating product with a strong early launch.
• Strategic and therapeutic fit with Neurocrine's existing business and expertise.
• Strengthens the company's growth profile and diversification.
• Clear, well-defined patient population with high unmet need.

⚠️ Risks:

• Integration challenges and the need to maintain commercial momentum during the transition.
• The long-term patient persistence on the drug (how long patients stay on it) is still being determined.
• Potential for future competitive entries in the PWS space.
• The deal's value is heavily reliant on the US market only at this time.

🔮 What's Next

1. Complete the Acquisition: Neurocrine will formally launch the tender offer for Soleno shares.
2. Integrate & Execute: The primary focus will be on seamlessly integrating Soleno's team and continuing the commercial launch of VYKAT XR in the US.
3. Build the Portfolio: Neurocrine will continue developing its internal pipeline (like drugs for CAH and obesity) alongside its now three-commercial-product portfolio.

🧠 The Analogy

This acquisition is like a successful restaurant chain (Neurocrine) buying a popular new food truck (Soleno) that has just invented a wildly popular, unique dish (VYKAT XR). The chain has the infrastructure, marketing muscle, and know-how to scale the dish to thousands more customers nationwide, turning a local hit into a national staple on their menu.

🧩 Final Takeaway

Neurocrine is spending nearly $3 billion to buy a proven, first-in-class drug for a rare disease, instantly accelerating its growth. The move is a calculated bet on expanding its endocrinology leadership, betting that its commercial expertise can scale VYKAT XR into a blockbuster alongside its existing medicines.